HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD
发明人:
Abraham RUTENBERG,Ronny UZANA,Michal LOTEM,Arthur MACHLENKIN,Galit EISENBERG,Tamar PERETZ-YABLONSKY,Shoshana FRANKENBURG,Roni ENGELSTEIN
申请号：
US16417048
公开号：
US20190330303A1
申请日:
2019.05.20
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
